Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU4-25P (RNA, U4 small nuclear 25, pseudogene) is annotated as a **pseudogene** of the small nuclear RNA (snRNA) family in humans[1][2]. As a pseudogene, it does not produce a functional RNA or protein product and is not considered active in canonical molecular or disease processes. Functional U4 small nuclear RNA genes (e.g., RNU4-2) are essential components of the major spliceosome complex and play a critical role in pre-mRNA splicing, but RNU4-25P itself does not encode a functional snRNA and thus does not perform these biological functions. No known therapeutic drugs target RNU4-25P, and it is not classed as a druggable target, biomarker, or safety concern for any disease[1][2]. **Summary of core issues:** - RNU4-25P is a **non-functional snRNA pseudogene** — not a receptor, enzyme, transporter, or known drug target[1][2]. - The functional gene family member is RNU4-2 (U4 snRNA), not RNU4-25P[3][4][5]. - No biological, therapeutic, or diagnostic role attributed to RNU4-25P in current research databases[1][2]. - The gene is correctly identified and named; the issue is that it is not a genuine molecular target. **Note on ambiguity:** There is confusion in the literature between **functional U4 snRNA genes** (e.g., RNU4-2, which are linked to neurodevelopmental disease when mutated[3][4][5]) and numerous *pseudogenes* like RNU4-25P, which are noncoding and non-functional. For disease roles, spliceosomal snRNA variants do play critical roles (such as in ReNU syndrome), but this *does not apply* to RNU4-25P specifically[3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U4 small nuclear 25, pseudogene (RNU4-25P).